

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).

Title: SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).

Publication year: 2021

Journal: European journal of cancer (Oxford, England : 1990)

Authors: Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France. Electronic address: marie-lea.gauci@aphp.fr.

Society: American College of Cardiology

Origin country: United States

Target countries: United States

DOI: 10.1016/j.ejca.2021.02.003

PMID: 33743480

Source: <https://pubmed.ncbi.nlm.nih.gov/33743480/>

pmc Eur J Cancer Eur J Cancer 3815 pheelsevier 9005373 European Journal of Cancer 0959-8049 1879-0852 pmc-is-collection-domain yes pmc-collection-title Elsevier - PMC COVID-19 Collection PMC7891073 PMC7891073.1 7891073 7891073 33743480 10.1016/j.ejca.2021.02.003 S0959-8049(21)00069-1 1 Letter to the Editor SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) Gauci Marie-Léa a * Coutzac Clélia b Houot Roch c Marabelle Aurélien d e Lebbé Céleste a on behalf of the FITC a Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France b Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Lyon, France c Centre Hospitalier Universitaire de Rennes, Service D'Hématologie Clinique, Rennes, France d Gustave Roussy, Université Paris-Saclay, Département D'Innovation Thérapeutique et D'Essais Précoces, Villejuif, France e Gustave-Roussy, Université Paris-Saclay, INSERM U1015 & CIC1428, Villejuif, France * Corresponding author : Dermatology department, INSERM U976 Saint-Louis Hospital 1, Avenue Claude Vellefaux 75010, Paris, France. 5 2021 18 2 2021 148 375649 121 123 10 2 2021 10 2 2021 18 02 2021 19 02 2021 19 12 2022 © 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Keywords SARS-CoV-2 vaccines mRNA-based vaccine Cancer Immunotherapy COVID- 19 FITC pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Dear Editor,

Since December 2019, the emergence of the severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2, responsible for COVID-19 and its worldwide spread led to devastating medical, economic and social consequences. Recently approved anti-SARS-CoV-2 vaccines (SC2V) offer a new hope to end this crisis.

Cancer patients (CPs) represent a group at higher risk of severe COVID-19 because of the underlying disease, mostly during the five years after cancer diagnosis and in case of active disease [1] but also because of their age and preexisting conditions [2].

Two mRNA-based SC2V have been recently approved by the EMA (BNT162b2, Pfizer Inc./BioNTech SE; and mRNA-1273, Moderna Inc.) and consist of lipid-nanoparticles- encapsulated mRNA that encodes the SARS-CoV-2 spike protein (SSP). On cell penetration, mRNA will be translated into the SSP, where degraded peptides are presented by MHC molecules to trigger an antigen-specific cellular and humoral immune response (IR) against SSP epitopes. Of note, the viral mRNA is subsequently degraded, thus it cannot interfere significantly with the host genome nor persist overtime. Phase 3 clinical trials (CTs) evaluating these vaccines versus placebo demonstrated remarkable efficacy with more than 90% (95 and 94.1%, respectively) protection against COVID-19 development and a favourable safety profile [3 , 4]. Although the efficiency of vaccination to prevent SARS-CoV-2 asymptomatic infection and transmission was not robustly explored in these phase 3 CTs, there was a trend in a decrease in PCR positivity before the second injection in the vaccine group (0.1% versus 0.3%) [3]. Further studies are needed to address this question.

In the BNT162b2 CT (Pfizer Inc./BioNTech SE) only, 4% of patients in the vaccine group suffered of any malignancy. Metastatic solid tumour, leukaemia and lymphoma represented 0.2% of all patients. Although robust data on efficacy and safety in this category of patients are lacking and because none of these patients received immunosuppressive treatment such as chemotherapy [3 , 4], it is expected that the safety of such non-live vaccines should be similar to that of patients without cancer. The ability of CP to build a strong, durable anti-SARS-CoV-2 IR with these mRNA-based vaccines shall be investigated in future trials.

Recently, the EMA has approved of the ChAdOx1 nCoV-19 codeveloped by AstraZeneca and Oxford University based on the results of 4 randomised CTs demonstrating an efficacy of ~60% with only mild local and systemic reactions [5]. This vaccine is a replication-deficient simian adenovirus expressing full-length SSP used here as a vector for transfection of SSP nucleic acid sequence into host cells, which will express SSP without viral replication. Therefore, it cannot be considered as a “live” vaccine such as BCG. Of note, its efficacy in the elderly population could not be formally demonstrated because few patients in those trials were over 55 years old. However, COVID-19 protection is expected in these patients given that an IR against the SSP was generated in this age group. The vaccine can be used in adults aged >55 years as per EMA recommendation.

Immune checkpoint inhibitors (ICI), such as anti-PD-(L)1 and anti-CTLA-4, restore an efficient anti-tumor IR by blocking inhibitory synapses. Considering their mechanism of action and based on preclinical data, ICI are likely to enhance rather than diminish IR against vaccines. Although the susceptibility of immunotherapy-treated patients to infections has not been specifically investigated, immunosuppression is not expected with these treatments and efficient postvaccinal seroconversion was already demonstrated with influenza vaccines [6 , 7]. However, CPs receiving steroids or cytokine blockers to manage immune-related side effects may not mount a robust IR against vaccines, but this aspect has not yet been evaluated. Patients with haematologic malignancies receiving B-cell-directed immunotherapies, typically CD19, CD20 or CD22-targeted therapies, may also be less responsive to SC2V [8]. In light of these data, the FITC (French society for ImmunoTherapy of Cancer) elaborated the following recommendations (summarised in Table 1) on the EMA-approved SC2Vs for CPs treated with immunotherapy: ♦ Healthcare workers caring for CPs treated with immunotherapy should receive SC2V to minimise virus transmission (based on data on influenza vaccine [9]). Because it is not yet formally proven that the vaccine prevents transmission of the virus to others, we recommend to maintain social distancing and masking even after vaccination [10].

Anti-SARS-CoV-2 vaccination should be made available broadly to CPs under immunotherapy but considered individually, notably in patients with known severe food, drug or excipient allergies.

CPs receiving ICI alone or in combination with anti-angiogenics or intratumoral oncolytic virus should receive an approved SC2V at any time of their treatment.

CPs treated with a combination of ICI and chemotherapy should be prioritised due to their immunocompromised condition. They shall ideally receive their first SC2V dose 3 weeks before starting their chemotherapy or in ongoing treatment conditions, as close as possible and before the next chemotherapy to improve its immunogenicity.

CPs treated with B-cell-directed immunotherapies (monoclonal antibodies, bi-specific T-cell engagers or CAR-T cells) should ideally receive their first dose of vaccine 3 weeks before starting treatment (including conditioning regimen for CAR-T cells). For patients who have already received haematopoietic stem cell transplantation or a CAR-T cell therapy, we recommend starting vaccination at least 3 months after therapy to allow immune recovery and optimise vaccinal response.

Patients in CTs should not be prevented from receiving SC2V and efforts are needed for CT protocols and sponsors to allow for concurrent vaccination. In phase I immunotherapy trials, patients should ideally receive a first vaccine dose at least 3 weeks before cycle 1 but should not receive any dose during the DLT period to avoid confusing unrelated adverse events.

Close monitoring of CPs treated with immunotherapy and vaccinated against SARS-CoV-2 should be performed through CTs and registries to assess potential adverse events, measure biological and clinical outcomes, and determine optimal protocols for anti-SARS-CoV-2 immunisation, notably:

The capacity to build a strong anti-SARS-CoV-2 IR.

The impact of the sequence of vaccination/immunotherapy on the efficacy/safety of both vaccination and immunotherapy and potential interactions.

FITC recommendations for COVID-19 vaccination in cancer patients treated with immunotherapy.

Finally, continued research with CTs and registries should be encouraged to generate more data on vaccine efficacy/safety in immunotherapy-treated CPs. FITC's recommendations could be modified on availability of new data.

FITC did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors in relation with the current statement about anti SARS-CoV-2 vaccine.

Authors declare no competing interest in relation with this letter.